Table 2 The differences in prevalence of studied clinical characteristics between patients positive and negative for SARS-CoV-2.

From: Symptom-based early-stage differentiation between SARS-CoV-2 versus other respiratory tract infections—Upper Silesia pilot study

Clinical characteristic

N (SARS-CoV-2 (−) / SARS-CoV-2 ( +))*

SARS-CoV-2 (-) Mean value ± SD

SARS-CoV-2 ( +) Mean value ± SD

OR

(95% CI)

OR effect interpretation

OR p-value ***

Age (years)

1938 (1354/584)

42.58 ± 14.68

43.34 ± 13.30

1.00 (1.00–1.01)

Negligible

0.2826

Baseline Sp02 w/o oxygen supplementation (%)

1887 (1312/575)

97.19 ± 1.27

97.05 ± 1.38

0.93 (0.86–1.00)

Negligible

0.0400

Temp. in hospital [oC]

1849 (1282/567)

36.51 ± 0.46

36.50 ± 0.51

0.98 (0.79–1.20)

Negligible

0.8094

Clinical characteristic (Yes)

N (SARS-CoV-2 (-) / SARS-CoV-2 ( +))

SARS-CoV-2 (-) N (%)*

SARS-CoV-2 ( +) N (%)*

OR (95% CI)

OR effect interpretation

OR p-value***

Sex **

1940 ι(1354/586)

F: 680 (50.22%)

F: 273 (46.59%)

0.87 (0.71–1.05)

Negligible

0.1416

Allergies

1941 (1355/586)

47 (3.47%)

8 (1.37%)

0.46 (0.23–0.91)

Small

0.0264

Heart diseases

1941 (1355/586)

89 (6.57%)

24 (4.10%)

0.64 (0.41–1.00)

Small

0.0515

Lung disease

1941 (1355/586)

29 (2.14%)

4 (0.68%)

0.44 (0.18–1.05)

Small

0.0655

Asthma

1941 (1355/586)

71 (5.24%)

20 (3.41%)

0.68 (0.42–1.11)

Small

0.1219

Diabetes

1941 (1355/586)

71 (5.24%)

22 (3.75%)

0.75 (0.46–1.20)

Negligible

0.2227

Hypertension

1941 (1355/586)

250 (18.45%)

100 (17.06%)

0.91 (0.70–1.17)

Negligible

0.4662

Kidney diseases

1941 (1355/586)

17 (1.25%)

6 (1.02%)

0.96 (0.42–2.22)

Negligible

0.9313

Blood type

N(SARS-CoV-2 (-) / SARS-CoV-2 ( +))

SARS-CoV-2 (-) N (% of 477)

SARS-CoV-2 ( +) N (% of 256)

OR (95% CI)

OR effect interpretation

OR p-value***

0

292 (196/96)

196 (41.09%)

96 (37.50%)

Serving as reference

A

260 (162/98)

162 (33.96%)

98 (38.28%)

1.24 (0.87–1.75)

Negligible

0.2371

B

112 (76/36)

76 (15.93%)

36 (14.06%)

0.97 (0.61–1.54)

Negligible

0.8881

AB

69 (43/26)

43 (9.01%)

26 (10.16%)

1.23 (0.72–2.13)

Negligible

0.4484

  1. * % calculated referring to N of particular characteristics in SARS-CoV-2(-) and SARS-CoV-2( +).
  2. ** Characteristics for sex were provided considering men as reference.
  3. *** Unadjusted p-value.
Back to article page